EyePoint Pharmaceuticals Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 EyePoint Pharmaceuticals Inc 公司

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.

EyePoint Pharmaceuticals Inc简介



公司代码EYPT

公司名称EyePoint Pharmaceuticals Inc

上市日期Jan 27, 2005

CEODuker (Jay S)

员工数量165

证券类型Ordinary Share

年结日Jan 27

公司地址480 Pleasant Street, Suite C400

城市WATERTOWN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02472

电话16179265000

网址https://eyepointpharma.com/

公司代码EYPT

上市日期Jan 27, 2005

CEODuker (Jay S)

EyePoint Pharmaceuticals Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Jay S. Duker, M.D.

President, Chief Executive Officer, Director

753.40K

+67787.00%

Ms. Nancy S. Lurker

Executive Vice Chairman of the Board

653.26K

+87799.00%

Dr. John B. Landis, Ph.D.

Non-Executive Independent Director

142.86K

+121464.00%

Ms. Karen L. Zaderej

Non-Executive Independent Director

117.28K

+2000.00%

Mr. Stuart Duty

Non-Executive Independent Director

45.01K

+45014.00%

Mr. Ramiro Ribeiro, M.D., Ph.D.

Chief Medical Officer

39.06K

--

Dr. Goeran A. Ando, M.D.

Non-Executive Independent Chairman of the Board

--

Ms. Wendy F. Dicicco, CPA

Non-Executive Independent Director

--

Mr. George Elston

Chief Financial Officer, Executive Vice President

--

Mr. Stern

Investor Relations

--

名称

名称/职务

职务

持股

持股变动

Dr. Jay S. Duker, M.D.

President, Chief Executive Officer, Director

753.40K

+67787.00%

Ms. Nancy S. Lurker

Executive Vice Chairman of the Board

653.26K

+87799.00%

Dr. John B. Landis, Ph.D.

Non-Executive Independent Director

142.86K

+121464.00%

Ms. Karen L. Zaderej

Non-Executive Independent Director

117.28K

+2000.00%

Mr. Stuart Duty

Non-Executive Independent Director

45.01K

+45014.00%

Mr. Ramiro Ribeiro, M.D., Ph.D.

Chief Medical Officer

39.06K

--

收入明细

单位: USD更新时间: 1月6日周二

FY2024

FY2023

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

业务USD

名称

营收

占比

YUTIQ

3.10M

7.16%

地区USD

名称

营收

占比

United States

42.05M

97.17%

China

1.12M

2.60%

United Kingdom

100.00K

0.23%

业务

地区

业务USD

名称

营收

占比

YUTIQ

3.10M

7.16%

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

Cormorant Asset Management, LP

9.98%

Suvretta Capital Management, LLC

7.48%

Adage Capital Management, L.P.

6.72%

The Vanguard Group, Inc.

5.82%

BlackRock Institutional Trust Company, N.A.

5.17%

其他

64.82%

持股股东

占比

Cormorant Asset Management, LP

9.98%

Suvretta Capital Management, LLC

7.48%

Adage Capital Management, L.P.

6.72%

The Vanguard Group, Inc.

5.82%

BlackRock Institutional Trust Company, N.A.

5.17%

其他

64.82%

股东类型

持股股东

占比

Hedge Fund

32.77%

Investment Advisor

25.09%

Investment Advisor/Hedge Fund

20.77%

Research Firm

4.26%

Private Equity

3.39%

Individual Investor

2.96%

Venture Capital

2.58%

Bank and Trust

1.06%

Pension Fund

0.13%

其他

7.00%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

386

74.75M

90.29%

-14.30M

2025Q3

373

69.94M

127.01%

+1.23K

2025Q2

381

69.95M

127.71%

-5.27M

2025Q1

371

75.32M

126.89%

-11.89M

2024Q4

359

75.24M

109.81%

+11.20M

2024Q3

343

59.71M

126.62%

+193.11K

2024Q2

330

60.06M

120.79%

+1.75M

2024Q1

313

56.72M

108.78%

+2.51M

2023Q4

268

50.21M

76.86%

+16.41M

2023Q3

224

33.81M

98.97%

+2.98M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Cormorant Asset Management, LP

8.27M

9.98%

-60.00K

-0.72%

Dec 04, 2025

Suvretta Capital Management, LLC

6.19M

7.48%

-611.38K

-8.99%

Sep 30, 2025

Adage Capital Management, L.P.

5.56M

6.72%

-1.24M

-18.24%

Sep 30, 2025

The Vanguard Group, Inc.

3.79M

4.58%

-8.13K

-0.21%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

4.28M

5.17%

-316.39K

-6.88%

Sep 30, 2025

Franklin Advisers, Inc.

4.14M

5%

-130.85K

-3.07%

Sep 30, 2025

Federated Hermes Global Investment Management Corp.

3.58M

4.32%

-1.46K

-0.04%

Sep 30, 2025

TCG Crossover Management, LLC

3.57M

4.32%

--

Sep 30, 2025

Citadel Advisors LLC

2.14M

2.58%

-208.82K

-8.91%

Sep 30, 2025

Paradigm BioCapital Advisors LP

2.01M

2.42%

+2.01M

--

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Virtus LifeSci Biotech Clinical Trials ETF

1%

Simplify Health Care ETF

0.99%

State Street SPDR S&P Pharmaceuticals ETF

0.98%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

0.95%

Invesco Dorsey Wright SmallCap Momentum ETF

0.36%

Federated Hermes MDT Small Cap Core ETF

0.3%

iShares Micro-Cap ETF

0.15%

iShares Health Innovation Active ETF

0.15%

ProShares Ultra Nasdaq Biotechnology

0.12%

Invesco Nasdaq Biotechnology ETF

0.09%

Virtus LifeSci Biotech Clinical Trials ETF

占比1%

Simplify Health Care ETF

占比0.99%

State Street SPDR S&P Pharmaceuticals ETF

占比0.98%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比0.95%

Invesco Dorsey Wright SmallCap Momentum ETF

占比0.36%

Federated Hermes MDT Small Cap Core ETF

占比0.3%

iShares Micro-Cap ETF

占比0.15%

iShares Health Innovation Active ETF

占比0.15%

ProShares Ultra Nasdaq Biotechnology

占比0.12%

Invesco Nasdaq Biotechnology ETF

占比0.09%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

公告日期

除权除息日

类型

比率

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1